Zelda Therapeutics makes significant progress in medicinal cannabis research programs

Listed medicinal cannabis company Zelda Therapeutics (ASX: ZLD) has made progress in a number of key research programs during the March 2018 financial quarter. Zelda recently received approval for a major study into the pharmacology of cannabinoids in the treatment of paediatric autism patients.

Read More

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.